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ABSTRACT  Soluble interleukin-2 receptor (sIL-2R) is produced by activated lymphocytes or 
malignant lymphoma (ML) cells. The aim of this study was to estimate the diagnostic role of 
serum sIL-2R levels in ML. 
   The data of serum sIL-2R levels were extracted from the database of 1278 untreated patients 
admitted to Kawasaki Medical School Hospital from 1997 to 2008 and retrospectively analyzed. 
   We compared the serum sIL-2R levels of 443 patients newly diagnosed with ML with 
those of 835 patients with non-hematological diseases to improve the diagnostic accuracy. 
The serum sIL-2R levels of patients with ML (median:1330 U/ml, range:197-84200) were 
significantly (p<0.001) higher than those with non-hematological diseases (median:827 U/
ml, range:106-18100). In the univariate analysis, the non-adjusted odds ratio was 3.123 and 
the specificity was 0.77 by adjusting the cut-off value of the sIL-2R level at 1500 U/ml. These 
findings suggested that sIL-2R is useful by itself in the differential diagnosis of ML. In the 
multivariate analysis, the adjusted odds ratio adding age ( ≧60 years), WBC counts (<10000/μ
l) and CRP levels (<0.4 mg/dl) to sIL-2R were 4.047. 
   Serum sIL-2R levels are useful for the diagnosis of ML, and the diagnostic accuracy of ML is 
improved by adding the other factors such as age, WBC counts and CRP levels to sIL-2R.  
 (Accepted on January 19, 2011)
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INTRODUCTION
   Malignant lymphoma (ML) is one of the 
malignant diseases arising from the lymphoid 
t i ssues .  As  i t  i s  he terogenous  in  terms of 
classification, the process of definitive diagnosis 
is obtained by the histological diagnosis of tissue 
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specimens. In addition, the stage and prognosis of 
patients with ML is estimated by the Ann Arbor 
classification and by the International Prognostic 
Index (IPI) composed of age, performance status, 
serum LDH level, number of extranodal lesions and 
the stage１，２）. Although histological diagnosis is 
absolutely essential for a definitive diagnosis, there 
is a need for a prudent choice because a biopsy is 
an invasive procedure and most in patients enlarged 
lymph nodes or fever of unknown origin (FUO) are 
composed of non-hematological, infectious diseases 
or autoimmune diseases.  
   Interleukin-2 (IL-2) is released from activated 
T-cells and transmits a growth signal after ligation 
to the interleukin-2 receptor (IL-2R)３）. IL-2R has 
at least three glycopeptide subunits composed of 
α, β and γ chains. IL-2Rαchain notably has 
a molecular weight of 55kDa and is known as 
Tac antigen４，５）. Rubin, et al. have proven that 
IL-2R α is released from the cell membrane in 
a soluble form (soluble IL-2R; sIL-2R)６，７）. An 
enzyme-linked immunosorbent assay (ELISA) 
with IL-2R α antibody has enabled the detection 
and quantification of the released soluble form６）. 
It is expressed not only on the surface of activated 
normal T-cells and B-cells８）but also on malignant 
lymphoid cells９，10）. Its serum level correlates with 
disease activity, tumor burden, prognosis and relapse 
in Hodgkin’s lymphoma (HL)11，12）, non-Hodgkin’
s lymphoma (N-HL)13－17）, chronic lymphocytic 
leukemia (CLL)18）and adult T-cell leukemia/
lymphoma (ATLL)19，20）. In addition, the level of 
sIL-2R is often elevated by non-hematological 
diseases including collagen diseases, solid tumors 
and infectious diseases21－24）. Therefore, it has long 
been a difficult problem for clinical physicians to 
determine the borderline of serum sIL-2R level 
between ML and non-hematological diseases. 
   In this study, we compared the serum sIL-2R 
levels in 443 patients with ML with those in 835 
patients with non-hematological diseases and 
evaluated the role of sIL-2R in newly diagnosed 
ML.     
PATIENTS AND METHODS
Patient population
   The study data consisted of 443 patients with a 
newly diagnosed ML admitted to Kawasaki Medical 
School Hospital from January 1997 to December 
2008 (defined as the ML group). Most of them were 
diagnosed with ML based on the results of a lymph 
node biopsy. The histology of ML was defined 
according to the World Health Organization (WHO) 
2008 classifications25）. The patient characteristics 
are shown in Table 1. Of these 443 patients, 346 
were diagnosed with B-cell lymphoma, 63 with 
T-cell and NK-cell lymphoma including 17 patients 
with ATLL, and 26 with Hodgkin’s lymphoma. 
Indolent lymphoma was of the B-cell lineage in 
103 patients, including 3 with chronic lymphocytic 
leukemia, 3 with lymphoplasmocytic lymphoma, 2 
with splenic marzinal zone B-cell lymphoma, 1 with 
plasma cell myeloma, 26 with extranodal marzinal 
zone lymphoma of mucosa-associated lymphoid 
tissue, 68 with follicular center lymphoma (grade
Ⅰ/Ⅱ). Aggressive lymphoma was of the B-cell 
lineage in 243 patients and of the T-cell or NK-cell 
lineage in 65.  The aggressive B-cell lymphoma 
was mantle cell lymphoma in 13 patients, follicular 
center lymphoma (grade Ⅲ) in 11, diffuse large 
B-cell lymphoma, not otherwise specified (NOS) 
in 206 patients, primary mediastinal large B-cell 
lymphoma in 4 patients, intravascular large B-cell 
lymphoma in 5 patients and Burkitt lymphoma in 4 
patients.  Aggressive NK-cell lymphoma was found 
in 2 patients, extranodal NK/T-cell lymphoma, nasal 
type in 5, enteropathy-associated T-cell lymphoma 
in 1, peripheral T-cell lymphoma, not otherwise 
specified (NOS) in 15 ,  angioimmunoblastic 
lymphoma (AILD) in 15, anaplastic large cell 
lymphoma in 8 and T-lymphoblastic leukemia/
lymphoma in 2 patients.
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   Clinical staging was assessed according to the 
Ann Arbor classification. The evaluation included 
a complete history and physical examination, a 
chest roentgenography, a bone marrow aspiration 
and biopsy, a computed tomography of the chest, 
abdomen and pelvis, a hemogram and routine 
biochemistry examinations.  
   The population of the non-hematological diseases 
group consisted of 835 patients with the newly 
diagnosed diseases unrelated to hematological 
disorders (defined as the non-hematological group). 
These patients’ characteristics are shown in Table 
2. We divided them into 6 categories composed 
of autoimmune diseases, non-hematological 
tumors, infections, fever of unknown origin, 
lymphadenopathy and others. 
Data collection
   This study was a retrospective analysis. The data 
on clinical parameters including age, gender, white 
blood cell (WBC) counts, serum C-reactive protein 
(CRP), serum LDH levels, and serum sIL-2R 
levels were extracted from the database of medical 
treatment records in Kawasaki Medical School 
Hospital. The parameters used in this study were 
obtained at the initial diagnosis. The entire study 
using patients’ data was approved by the ethical 
committee of Kawasaki Medical School.  
ELISA for sIL-2R
   The serum sIL-2R levels were measured with a 
sandwich ELISA (Cell-free Interleukin-2 Receptor 
Test Kit, T Cell Science, Cambridge, Mass., USA) 
based on two monoclonal antibodies raised against 
two different epitopes of the p55 alpha-chain of 
the IL-2R complex. The normal range of this was 
defined as from 220~530 U/ml in Japan. 
Statistical analyses
   All results were shown as median values with 
ranges. Comparisons between the groups were 
done using the Mann-Whitney U test. Multivariate 
analysis to define independent factors was 
performed using the multivariate logistic regression 
model. These data were considered statistically 
significant if p-values were less than 0.05. The 
analyses were carried out using SPSS for Windows 
version14.0.
RESULTS
The comparison of the serum soluble IL-2 receptor 
levels and other parameters between the two groups
Table 2.　Patient data with non-hematological diseases
Histology No of cases
Age
(years)
median
(range)
M/F
sIL-2R
(U/ml)
median
(range)
WBC
(/ml)
median
(range)
CRP
(mg/dl)
median
(range)
LDH
(IU/L)
median
(range)
Non-hematological group
Autoimmune diseases
Non-hematological tumors
Infections
Fever of unknown origin
Lymphadenopathy
Others
126
188
204
51
63
203
55
(16-82)
66
(13-91)
62
(0-97)
38
(3-84)
58
(2-87)
63
(15-88)
42/84
114/74
118/86
24/27
40/23
123/80
998
(106-14000)
741
(252-4490)
1025
(131-18100)
612
(264-8490)
896
(245-5030)
657
(156-6260)
6420 
(2080-29500)
6515 
(20-26560)
6560 
(1500-28620)
6440 
(2330-17850)
7100 
(2760-19570)
6060 
(1390-17190)
0.84
(0.03-29.70)
0.47
(0.03-32.00)
0.78
(0.02-31.50)
0.28
(0.03-22.60)
1.08
(0.03-27.89)
0.26
(0.02-26.98)
192
(99-737)
206
(105-3220)
200
(106-2517)
201
(120-634)
183
(116-371)
200
(94-1238)
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Table 3.　The impact of serum sIL-2R level on  the diagnosis of malignant lymphoma by univariate analysis
sIL-2R ML
non
hematological
diseases
sensitivity speciﬁcity
non-adjusted
odds ratio
(95%conﬁdence
interval)
positive 
predictive
value
likelihood
ratio
≧500
<500
≧1000
<1000
≧1500
<1500
≧2000
<2000
≧2500
<2500
≧3000
<3000
≧4000
<4000
≧5000
<5000
370
73
262
181
213
230
180
263
163
280
149
294
124
319
103
340
624
211
344
491
191
644
136
699
95
740
68
767
36
799
22
813
0.83
0.59
0.48
0.40 
0.37
0.34
0.28
0.23
0.25
0.59
0.77
0.84
0.89
0.92
0.96
0.97
1.714
(1.275-2.303)
2.066
(1.635-2.611)
3.123
(2.440-3.996)
3.517
(2.702-4.580)
4.535
(3.400-6.048)
5.716
(4.164-7.847)
8.627
(5.823-12.782)
11.195
(6.945-18.045)
0.372
0.432
0.527
0.569
0.631
0.686
0.775
0.824
1.118
1.436
2.102
2.495
3.234
4.130 
6.492
8.825
Fig. 1.  Differences in the levels of several parameters 
between the malignant lymphoma group and the non-
hematological group by box and whisker plots.
　The central box indicates the range from 25 percentiles 
and 75 percentiles of the measured values with the median 
value shown by the horizontal line in each box. The vertical 
whiskers extend to 5 percentiles and 95 percentiles of the 
measured values. The levels of sIL-2R, WBC, CRP and LDH 
level are compared between the ML group (n=443) and the 
non-hematological group (n=835).
   Patients with ML (443 cases) and patients with 
non-hematological diseases (835 cases) were 
enrolled in this study. The median age of patients in 
the ML group was 65 years old (range: 6~90) and 
61 years old (range: 0~97) in the non-hematological 
group, respectively (data not shown). The age 
distribution in the ML group tended to be higher 
than that in the non-hematological group. 
   The serum sIL-2R levels and other parameters 
including WBC, CRP and LDH were compared 
between the ML group and the non-hematological 
group (Fig. 1). The serum sIL-2R levels in the ML 
group (median 1330U/ml, range: 197~84200) were 
significantly (p<0.001) higher than that of the non-
hematological group (median 827 U/ml, range: 
106~18100). The level of LDH in ML group (median 
216 IU/L, range: 34~7325) was significantly 
(p<0.001) higher than that of the non-hematological 
group (median 200 IU/L, range: 94~3220). 
   The WBC count in the ML group (median 
5790/μl, range: 1600~109150) was significantly 
(p<0.001) lower than that of the non-hematological 
group (median 6440/μl, range: 20~29500). The 
level of CRP in the ML group (median 0.30 mg/dl, 
range: 0.03~27.80) appeared to be lower than that 
of the non-hematological group (median 0.48 mg/
dl, range: 0.02~32.00), but the difference was not 
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statistically significant (p=0.087). 
The impact of serum sIL-2R level on the diagnosis 
of malignant lymphoma by the univariate analysis
   The patients in the ML group and those in the 
non-hematological group were divided into sIL-
2R-increase-positive and negative populations 
by adjusting the cut-off value of the sIL-2R level 
500~5000 U/ml by every 500 or 1000 U/ml (Table 
3). The sensitivity decreased from 0.83 to 0.23 
by incrementing the point of the cut-off value. In 
contrast, the specificity increased from 0.25 to 
0.97 by incrementing the point of the cut-off value. 
The non-adjusted odds ratio was increased by 
incrementing the point of the cut off value. When 
the cut-off value was adjusted at 1500 U/ml, the 
odds ratio was 3.123. Even when the cut-off value 
was adjusted to 5000 U/ml, the positive predictive 
value was 0.824 at the highest. 
   The percentages of 191 patients with more than 
1500 U/ml of sIL-2R in the non-hematological 
group was 15.1%, 22.5%, 22.4%, 6.1%, 7.5% and 
24.3% in autoimmune diseases, non-hematological 
tumors, infections, FUO, Lymphadenopathy and 
others, respectively (Fig. 2). The proportion of non-
hematological tumors decreased from 14.7% to 
0.0% by incrementing the point of the cut-off value. 
In contrast, the proportion of infections increased 
from 33.0 to 59.1% by incrementing the point of the 
cut-off value. 
Risk factors in the diagnosis of malignant lymphoma 
by multivariate analysis
   The multivariate analysis of the serum sIL-
2R level and five factors (age, gender, WBC 
count, LDH and CRP) was performed using the 
multivariate logistic regression model. Of those, 
age and LDH were selected to associate with the 
IPI index. Other parameters were taken from the 
gender difference of malignancy or factors related 
inflammation. The adjusted odds ratio of the sIL-2R 
level was elevated from 3.123 to 4.047 by including 
participants aged above 60 years, WBC of less than 
10000 /μl and CRP of less than 0.4 mg/dl to the 
sIL-2R cut-off value at 1500 U/ml (Table 4). 
DISCUSSION
   The serum sIL-2R level has long been investigated 
in various hematological diseases, such as ATLL, 
CLL, HL and non-Hodgkin’s lymphoma. Notably, 
a high serum sIL-2R level at the initial diagnosis 
of ML has been found to associate with a high 
Fig. 2.  The distribution of patients with non-hematological 
diseases who indicated more than 1500 U/ml of serum sIL-2R 
level
　We listed up the distribution of 191 patients with non-
hematological diseases with more than 1500 U/ml of serum 
sIL-2R level by adjusting the cut-off value of 1500~5000 
U/ml by every 500 or 1000 U/ml and divided them into 6 
categories. Each category was indicated above. 
Table 4.　Multivariate logistic regression model: risk factors for 
malignant lymphoma
risk factors n adjusted odds ratio(95% conﬁdence interval) p-value
Age
<60
≧60
sIL-2R
<1500
≧1500
WBC
<10000
≧10000
CRP
<0.4
≧0.4
538
740
874
404
1098
180
626
652
1.701 (1.316-2.198)
4.047 (3.057-5.357)
1.562 (1.075-2.270)
2.103 (1.601-2.762)
   
<0.001
<0.001
0.019
<0.001
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incidence of treatment failure, advanced stage 
and poor prognosis11－18）. On the other hand, the 
elevation of the serum sIL-2R level was also 
observed in autoimmune diseases, infections 
and non-hematological tumors other than ML21
－24）. Therefore, it was not necessarily a specific 
marker for lymphoid malignancies. Yasuda N, et al. 
reported the serum sIL-2R levels in patients with 
various diseases, such as hematological diseases, 
infectious mononucleosis and HIV infection22）. 
Nakase K, et al. reported that the sIL-2R level 
of hematological malignancies was significantly 
higher than that of solid tumors23）. Though it is 
natural that histopathological diagnosis using lymph 
node specimens is essential for diagnosis of ML, 
the role of serum sIL-2R level in the definitive 
diagnosis of ML or the differential diagnosis with 
non-hematological diseases has been acontroversial 
object. However, there have been few reports 
demonstrating the diagnostic accuracy of ML, 
including other risk factors, and the borderline of 
sIL-2R level between ML and non-hematological 
diseases26）.
   Goto H, et al. reported that the mean serum sIL-2R 
level of T-cell lymphoma patients was significantly 
higher than that of B-cell lymphoma patients15）. 
The serum sIL-2R level in patients with T-cell 
lymphoma except ATL (median 4415 U/ml, range: 
274~59400 U/ml) in our study was significantly 
(p<0.002) higher than that in patients with B-cell 
lymphoma (median 1220 U/ml, range: 197~52300 
U/ml). The median serum sIL-2R level of the stage I, 
II, III, IV in ML was 483 U/ml (range: 204~5520), 
812 U/ml (range: 197~12600), 1090 U/ml (range: 
274~21000) and 3300 U/ml (range: 287~59400), 
respectively. The median serum sIL-2R level of 
stage III, IV was significantly (p<0.01) higher than 
that of non-hematological diseases (median 827, 
range: 106~18100), but it was not the case in stage 
II (p=0.626). Serum sIL-2R is a valuable marker in 
patients with ML in the advanced phase.
   We divided the 835 cases in the non-hematological 
group into 6 categories. The level of serum sIL-
2R has previously been measured in various non-
hematological diseases. The majority of these 
reports have been occupied by 5 main categories 
that consisted of autoimmune diseases, neoplasia, 
allograft rejection, infections and others26）. We 
had no cases associated with allograft rejection 
and defined benign tumors and neoplasia, except 
hematological diseases, as non-hematological 
tumors. Furthermore, apart from the 5 categories, 
there were many cases of lymphadenopathy of 
unknown etiology and FUO which were difficult for 
a definitive diagnosis in this study. 
   The positive predictive value was upgraded to 
0.824 when the cut-off value of sIL-2R level was 
elevated to 5000 U/ml. The maximal value of sIL-
2R in non-hematological diseases was 18100 U/ml 
(a case with fulminant hepatitis). Because there were 
numerous cases indicating a sIL-2R level higher 
than 5000 U/ml in non-hematological diseases, it 
was difficult to determine the borderline between 
ML and non-hematological diseases. In general, 
tumor markers have been demonstrated not to be 
valuable for early diagnosis, but to be consistently 
useful as an adjunct to determine the progress and 
recurrence of diverse malignant diseases27－29）. 
   It is very interesting to consider whether the cut-
off level of 1500 U/ml on sIL-2R is correlated with 
event free survival (EFS) or overall survival (OS) 
in ML.  Kono N, et al. previously reported a cut-
off level of less than 1000U/ml on sIL-2R was 
associated with better survival in our country.  Goto 
H, et al. reported that patients with more than 2000 
U/ml   sIL-2R revealed a worse prognosis than 
those with a sIL-2R level of less than 2000. Oki Y, 
et al. reported the impact of sIL-2R for prognostic 
prediction was most apparent in ML patients with 
IPI low risk30）.  Further studies will be necessary in 
order to predict the prognosis of ML patients using 
the pretreatment sIL-2R level.   
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   The present study suggests that serum sIL-2R 
level plays a supplementary role in the definitive 
diagnosis of ML or in the differential diagnosis of 
FUO and undetermined lymphadenopathy through 
improving the diagnostic accuracy by adding other 
parameters to the serum sIL-2R level. We further 
intend to find the clinical utility of the serum sIL-
2R level by analyzing its relation to the lymphoma 
subtypes.
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